Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

This article discusses the JCCP's new Premises Standards for aesthetic practitioners, focusing on how these guidelines help ensure patient safety, and reports no new research findings.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This review analyzes the impact of different preparation methods for platelet-rich plasma, human follicles stem cells, and adipose-derived stem cells on hair regrowth and wound healing, but reports no new results; the authors emphasize convincing evidence of positive outcomes despite protocol variability.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This review discusses the National Alopecia Areata Foundation's efforts to evaluate and advance alopecia areata research, focusing on immunology and drug development, and reports no new clinical results.

In this study, researchers observed that twins with a novel de novo nonsense variant in HRAS exhibited distinctive features, including neuropsychiatric symptoms, potentially indicating a wider clinical spectrum for conditions known as RASopathies.

This article discusses the urgent issue of preserving freedom of choice in dermatology, highlighted by the American Academy of Dermatology, and reports no new research findings.

This study concluded that allele-specific PCR (AS-PCR) is more reliable than tetra-primer ARMS-PCR for genotyping the SNP rs1998076 due to better stability and interpretability.

In this mouse study, the absence of the Ascl4 gene did not affect the development of hair follicles, teeth, or mammary glands, suggesting it is non-essential for these processes.

This review discusses various extra facial esthetic indications of botulinum toxin, like neck rejuvenation and calf slimming, and reports no clinical results; essential tips for each indication are included.

This document only provides affiliation and role information for individuals associated with hair centers in Charlotte, North Carolina, and does not contain any research results or conclusions.

This article discusses the creation of Alopecia Areata Uniform Protocols by the National Alopecia Areata Foundation to standardize clinical trials for alopecia areata treatments and reports no new results.

This review discusses the formation and goals of the Pediatric Dermatology Research Alliance (PeDRA) but reports no new clinical results; it emphasizes collaborative research to advance treatment options for pediatric skin disorders.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

This article provides no abstract or new findings and focuses on a patient registry related to spasticity care.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study found that P144 (Disitertide) significantly reduced collagen deposition and improved muscle organization in a rabbit model of post-radiotherapy fibrosis, suggesting potential antifibrotic effects.

This case report describes a 4-year-old boy with autism and a rare condition causing precocious puberty, where treatment for hyperandrogenism unexpectedly intensified his aggressive behavior.

This study proposes that intranasal exposure to PTx and autoantigen in an animal model can trigger autoimmune disease, supporting the idea that subclinical nasal colonization by BP may cause alopecia areata.

This pilot study detailed the use of Hair-to-Hair-matching technology™ in a clinical trial to assess botulinum toxin's efficacy in treating male androgenetic alopecia, providing a precise method for evaluating hair count and thickness changes over time.

This study found that a novel nano-engineered platform, PCA, significantly promoted hair regeneration in an androgenetic alopecia mouse model by enhancing angiogenesis and hair follicle stem cell proliferation, showing promise for future hair regrowth treatments.

In this study, genetic testing confirmed the diagnosis of Androgen insensitivity syndrome in most CAIS patients in Tunisia and identified two previously unreported mutations in the androgen receptor gene.

This article reviews insights into the pathogenesis of primary cicatricial alopecias, such as lichen planopilaris, provided by emerging technologies, but it does not report new clinical results.

This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.